Head A, Maxwell S, Kendall M J
Department of Sport Sciences, Brunel University College, Isleworth, Middlesex, United Kingdom.
Br J Sports Med. 1997 Jun;31(2):120-5. doi: 10.1136/bjsm.31.2.120.
Previous studies have shown that beta 1 selective agents have fewer adverse effects on exercise metabolism than nonselective beta blockers, and this has been attributed to their reduced blockade of beta 2 receptors. This study aimed at determining whether a beta blocker with partial agonist activity at beta 1 and beta 2 receptors (celiprolol) was better than a conventional beta 1 receptor-blocker (atenolol) in prolonging exercise capabilities.
After four days of treatment with celiprolol 200 mg, atenolol 50 mg, or placebo, 22 healthy volunteers exercised on a treadmill for two hours at 50% of their maximal oxygen uptake. Resting heart rate and blood pressure were recorded before and after exercise. During exercise, fat oxidation, plasma free fatty acids, glycerol, glucose, and ammonia were measured together with heart rate and perceived exertion.
Mean exercising heart rate was significantly lower in those taking either of the beta blockers than in those taking placebo, and significantly lower for those taking atenolol rather than celiprolol. Fat oxidation was significantly lower for those taking celiprolol (38.8 (SD 12.2)%, P < 0.01) and atenolol (36.6 (15.9)%, P < 0.01) compared with placebo (45.6 (14.1)%). For the first 15 minutes of exercise, fat oxidation was significantly lower for those taking atenolol (24.6 (12.8)%, P < 0.01) than celiprolol (29.6 (14.3)%). The rise in plasma free fatty acids and glycerol during exercise was also significantly attenuated by both beta blockers in comparison with the rise in those taking placebo (P < 0.01).
Both celiprolol and atenolol reduced fat oxidation compared with placebo. For the first 15 minutes of exercise fat oxidation was preserved by celiprolol, but not atenolol. This preservation of fat oxidation during the early part of exercise may confer some small benefit to patients who take beta blockers and intend to exercise regularly. However, we did not detect significant differences between atenolol and celiprolol in overall mean fat oxidation or perceived exertion in this study.
既往研究表明,β1选择性药物对运动代谢的不良影响比非选择性β受体阻滞剂少,这归因于它们对β2受体的阻断作用减弱。本研究旨在确定一种在β1和β2受体具有部分激动活性的β受体阻滞剂(塞利洛尔)在延长运动能力方面是否优于传统的β1受体阻滞剂(阿替洛尔)。
22名健康志愿者分别接受200mg塞利洛尔、50mg阿替洛尔或安慰剂治疗4天后,在跑步机上以其最大摄氧量的50%进行两小时运动。记录运动前后的静息心率和血压。运动期间,测量脂肪氧化、血浆游离脂肪酸、甘油、葡萄糖和氨,同时记录心率和主观用力程度。
服用任何一种β受体阻滞剂者的平均运动心率均显著低于服用安慰剂者,且服用阿替洛尔者的心率显著低于服用塞利洛尔者。与安慰剂组(45.6(14.1)%)相比,服用塞利洛尔(38.8(标准差12.2)%,P<0.0l)和阿替洛尔(36.6(15.9)%,P<0.01)者的脂肪氧化显著降低。在运动的前15分钟,服用阿替洛尔者(24.6(12.8)%,P<0.01)的脂肪氧化显著低于服用塞利洛尔者(29.6(l4.3)%)。与服用安慰剂者相比,两种β受体阻滞剂也显著减弱了运动期间血浆游离脂肪酸和甘油的升高(P<0.01)。
与安慰剂相比,塞利洛尔和阿替洛尔均降低了脂肪氧化。在运动的前15分钟,塞利洛尔可维持脂肪氧化,但阿替洛尔不能。运动早期脂肪氧化的维持可能对服用β受体阻滞剂并打算定期运动的患者有一些小的益处。然而,在本研究中,我们未检测到阿替洛尔和塞利洛尔在总体平均脂肪氧化或主观用力程度方面的显著差异。